HBM-7020

N/A

Report date: 2026/03/19 17:23:04

Base Information

Drug NameHBM-7020
Drug Alias NameHBM-7020HBM7020R7020R-7020
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-BCMAAnti-CD3
TargetsB-cell maturation proteinT cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHarbour Biomed
China Registration ClassN/A

Develop Information

Active CompaniesHarbour BiomedOtsuka Pharmaceutical Co LtdHualan Ankang Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A